Original Contributions: PDF OnlyTemlett J. A.; Quinn, N. P.; Marsden, C. D.; Lataste, X.; Jaton, A. L.Clinical Neuropharmacology: February 1989 - p 55-59 Buy Abstract Summary CQA 206–291, a new D2 dopamine receptor agonist with a biphasic dopaminergic profile, was given to six patients with idiopathic Parkinson's disease after overnight drug withdrawal. With incremental single oral doses of CQA, a dose-related, clinically significant, and prolonged antiparkinsonian effect was observed. Most subjects experienced drowsiness after the drug while a minority of subjects experienced nausea and/or vomiting or postural hypotension. Further study of this drug in humans is indicated. © Williams & Wilkins 1989. All Rights Reserved.